|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Diabetes
In diabetes, there are elevated blood sugar levels due to absolute or relative insufficiencies of insulin. There are two types of diabetes: type 1 (previously called insulin-dependent diabetes mellitus (IDDM) or juvenile-onset diabetes) and type 2 (previously called non-insulin-dependent diabetes mellitus (NIDDM) or maturity-onset diabetes). There are signs that type 2 diabetes is being diagnosed more often in adolescents and young adults, due to sedentary lifestyles and 'fast-food' eating habits. Most type 2 diabetics produce variable, even normal, amounts of insulin, but have abnormalities in liver and muscle cells that resist its action.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
ALTITUDE Diabetes Study CSPP100E2337
The purpose of this clinical study is to determine if the study drug delays or prevents the occurrence of heart and/or kidney complications in participants with type 2 diabetes who are taking medications for hypertension, heart and/or kidney problems.
The study drug is approved by the US Food and Drug Administration (FDA) for the treatment of people with high blood pressure, however, it is not approved for treatment of people with type 2 diabetes.
Trial phase: Phase 3 Participation Duration: Depending on when participants join this study, their participation may last for two to four years with up to 23 scheduled visits. Protocol Number: CSPP100E2337 Diabetes Study CLAF237A 23138
The purpose of this clinical study is to determine if the study drug is safe to lower blood sugar in participants with diabetic nephropathy. Diabetic Nephropathy is a term used to describe kidney disease that occurs as a result of diabetes. This study drug is an investigational drug, which means it is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3b Participation Duration: The study will up to take up to 26 weeks (6 months 2 weeks). The participant will be required to visit the study center at least 9 times. After completing the study, participants may be asked to join a study extension. Protocol Number: CLAF237A 23138
Diabetes Study CACZ885I2202
The purpose of this study is to verify the dosage of the study drug and its effectiveness for participants who have type 2 diabetes and are currently taking or willing to begin taking metformin to treat their diabetes.
A “study drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 2/3 Participation Duration: This study will last a minimum of 3 years up to a maximum of 5 years. During the study, participants will be required to visit the study center once a month. Protocol Number: CACZ885I2202 Diabetes Study CLCQ908A2203
The purpose of this clinical study is to determine if the study drug helps to control high blood sugar in participants who are also taking metformin for the treatment of type 2 diabetes.
This study drug is an investigational drug, which means that it is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3 Participation Duration: Participants will be required to visit the study center for 3 initial screening visits. If accepted into the study, there will be 4 additional visits over a duration of 12 weeks. Protocol Number: CLCQ908A2203 |